Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.